Archive | 2017 Rayno Biopharmaceuticals Portfolio

The Rayno Biopharmaceuticals Portfolio up to date picks for 2017 are below.  We have recovered from the bear market for biotechnology stocks since the 2015 “bubble” peak of July 17, 2015. The sector bottomed on November 3, 2016 with IBB at  $246 and is up 19% YTD.

FED Fear Factor Fades then Biotechs Rally: AMGN,IBB…Update-1 Bearish Reversal

Update-1… 9/13… Hard to Call Next Move: Macro and i Rates Rule The market was rattled at the opening with the IEA news on cuts in the demand forecast for crude which dropped 2.33%. Subsequently FED hike fears returned causing more volatility with stocks and significantly a major move up in the Ten Year Treasury Yield […]

Continue Reading 0

Biotechs Get a Turbo Boost from Biogen(BIIB)…Update-1 GILD

Update-1… Gilead Sciences (GILD) Sells Off on earnings Gilead Sciences (GILD) sold off over 4% after hours after releasing second quarter sales of $7.7B and earnings of $3.08/sh. Q2 profit forecast beat. The full year revenue forecast was also cut slightly by $1B to the $29,5B-$31.5B range. Pricing pressures continued on Hep-C drugs and new […]

Continue Reading 0

Biotech Rally Up 8% from Brexit Bottom: Rayno Biopharmaceutical Portfolio Update: July 11, 2016…Update-1

Update-1… 7/12/16 Dow and S&P Hit Record Highs, Awaiting Q2 Earnings-Risk Still On-Biotech Stocks Lag The market continued its post-BREXIT rally helped by low interest rates and WTI crude up 4.56% to $46.80. Gold eased off and the dollar was up. We are still rallying off last Friday’s job report and Alcoa (AA) earnings yesterday. […]

Continue Reading 0

Foundation Medicine (FMI): New Pick Added To Raygent Core Portfolio

Foundation Medicine (FMI) New Pick at $20.40 We have added Foundation Medicine (FMI) to our core portfolio because of their leadership position in pharmacogenomics and molecular medicine for cancer care. The Foundation One genomic profile helps physicians make treatment decisions for patients with cancer by identifying the molecular growth drivers of their cancers and helping oncologists […]

Continue Reading 0

BRexit Bottom for Biotech Creates Buying Opportunity…Update-2

Update-2 …6/30 after the close Biotech stocks rallied again for the third day but momentum ebbed. Large caps were mainly in the green led by Alexion Pharmaceuticals (ALXN), Roche Holding (RHHBY) and Gilead Sciences (GILD). Mid-caps were mixed and well below recent highs. All of our core portfolio picks were up. Look to the XBI […]

Continue Reading 0

Rayno Biopharmaceuticals 2016 Update: 4/14 All In the Green!

 Rayno Biopharmaceutical Picks For 2016 Focus is larger cap stocks that pay dividends with one speculative pick (BLUE). XBI is a potential trade for momentum but the IBB can be used for larger cap rebalancing. New picks will be added should technicals in the sector hold. Large cap update after Q1 earnings reports. See comments […]

Continue Reading 0

Rayno Biopharmaceuticals Update 3/30-Stuck in a Trading Range with Upside Opportunities

Rayno Biopharmaceutical Portfolio Update- Biotechs with Upside Opportunity Caution No Rush to “Load Up” in a Bear Market Since Mid-January all of our previous portfolios were placed on hold and we recommended four new positions as long term holds. Here are initial prices and the current performance: Abbvie (ABBV) Started at $56.49 now at $56.96 […]

Continue Reading 0

Monday Movers in the Biotech Bear Market…ALNY, GILD, GWPH

Tuesday 12:45pm EDT Update on a red screen day: Healthcare sector lags down 1.6%, biotechs now being crushed IBB down 3.1%,XBI down 5%! ——– Look for Value +Growth Picks in a Biotech Bear Market Marijuana Strengthens Clinical Status Review our assumptions from previous posts: Biotech remains in a bear market so sector plays may not […]

Continue Reading 0

Biotech Stocks Get Traction But Still Lag Broader Market…Update-2…Rally Mode

Update-2… Broad Tradable Rally Continues 12:30 PM EST XBI leads IBB today up 4.2% vs 2.9%. XBI at $54 is now up 9.55% over 5 days and well off Feb. 11 bottom of $44. This is a broad rally today with most biotech stocks up  and the most speculative stocks are big movers. Check your holdings […]

Continue Reading 0

Large Cap Biopharma Winners and Losers 2015-16: Which Stocks Can Beat the ETFs?… Part 2

Rayno Large Cap Biopharmaceuticals…Part 2…A Stock pickers Market Time to Rebuild Your Portfolio: ABBV, BMY, GILD Below we have summarized selective metrics for large cap biopharmaceutical companies. We began the process of revising and rebalancing our portfolio after the J.P.Morgan Healthcare Conference. Here are some parameters to watch that should help in stock picking: Stock […]

Continue Reading 0